Our Parliamentary Affairs and Policy and Evidence teams have submitted their calls to the Government as part of the feedback process for the Spending Review.
INDIANAPOLIS, Jan. 29, 2025 /PRNewswire/ -- Roche announced today that the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug ...
It will be broadly available on cobas® c analyzers. In May 2024, as part of a separate FDA submission, the Roche Tina-quant Lp(a) RxDx assay, which is intended to support the selection of patients who ...
NEW YORK – Following the European launch of its new Cobas I 601 mass spectrometry analyzer in December, Roche is now preparing to release ... that has long been common to conventional clinical ...
If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...
Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, the Swiss pharmaceutical giant expects that, between 2023 and 2028, sales from these assets ...
Sir Brian Roche says there is a concern about the level of analysis given to Treaty "breaches". Photo / Marty Melville There are too many meetings in the public service, too many layers of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback